| Probe | Locus(GRCh37) | Gene | Region | p-val | Trait | PubMed ID |
| cg11023901 | chr7:140625783 | BRAF | Promoter | 1.399e-4 | Alcohol use disorders | 26763658 |
| Gene Symbol | Pearson Correlation Coefficient |
|---|---|
| RNMT | 0.963 |
| GSK3B | 0.96 |
| FAM126B | 0.959 |
| MAPK8 | 0.957 |
| UBE2K | 0.957 |
| AVL9 | 0.956 |
| ARHGEF7 | 0.956 |
| ENTPD4 | 0.956 |
| CCSAP | 0.955 |
| GLS | 0.954 |
| Gene Symbol | Pearson Correlation Coefficient |
|---|---|
| OR4F5 | -0.515 |
| OR4F29 | -0.473 |
| HEY2 | -0.445 |
| CSAG1 | -0.433 |
| COPZ2 | -0.426 |
| MYL3 | -0.425 |
| RAB13 | -0.407 |
| ASB4 | -0.399 |
| RHOD | -0.399 |
| MDFI | -0.396 |
| ID | Drug Name | Drug Type | CAS Num | Status | Role |
|---|---|---|---|---|---|
| DB00398 | Sorafenib | Small Molecule | 284461-73-0 | Approved|Investigational | Target |
| DB05190 | XL281 | Small Molecule | - | Investigational | Target |
| DB05984 | RAF-265 | Small Molecule | 927880-90-8 | Investigational | Target |
| DB06999 | N-{3-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl}propane-1-sulfonamide | Small Molecule | Experimental | Target | |
| DB07000 | N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide | Small Molecule | Experimental | Target | |
| DB08553 | (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime | Small Molecule | - | Experimental | Target |
| DB08881 | Vemurafenib | Small Molecule | 918504-65-1 | Approved | Target |
| DB08896 | Regorafenib | Small Molecule | 755037-03-7 | Approved | Target |
| DB08912 | Dabrafenib | Small Molecule | - | Approved|Investigational | Target |
| ID | Drug Name | Action | PubMed |
|---|---|---|---|
| C028474 | 1,4-bis(2-(3,5-dichloropyridyloxy))benzene | "CTNNB1 gene mutant form affects the susceptibility to [1,4-bis(2-(3,5-dichloropyridyloxy))benzene affects the expression of BRAF protein]" | 21705713 |
| C532162 | 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine | "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [BRAF protein mutant form results in increased susceptibility to GDC-0973]" | 22084396 |
| C111118 | 2',3,3',4',5-pentachloro-4-hydroxybiphenyl | "2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of BRAF mRNA" | 19114083 |
| C078765 | 2,3,5-(triglutathion-S-yl)hydroquinone | "2,3,5-(triglutathion-S-yl)hydroquinone results in increased expression of BRAF protein" | 21813464|2633301 |
| C078765 | 2,3,5-(triglutathion-S-yl)hydroquinone | "TSC2 protein affects the reaction [2,3,5-(triglutathion-S-yl)hydroquinone results in increased expression of BRAF protein]" | 21813464 |
| C023514 | 2,6-dinitrotoluene | "2,6-dinitrotoluene affects the expression of BRAF mRNA" | 21346803 |
| C023035 | 3,4,5,3',4'-pentachlorobiphenyl | "3,4,5,3',4'-pentachlorobiphenyl results in increased expression of BRAF mRNA" | 28973690 |
| C027576 | 4-hydroxy-2-nonenal | 4-hydroxy-2-nonenal results in decreased expression of BRAF mRNA | 12419474 |
| C012606 | 4-vinyl-1-cyclohexene dioxide | 4-vinyl-1-cyclohexene dioxide affects the expression of BRAF mRNA | 20829426 |
| C000603579 | A-1155463 | A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]] | 27689874 |
| C496492 | abrine | abrine results in increased expression of BRAF mRNA | 22595364 |
| C501332 | ABT-737 | ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]] | 27689874 |
| D000082 | Acetaminophen | Acetaminophen results in increased expression of BRAF mRNA | 21420995 |
| D000082 | Acetaminophen | Acetaminophen affects the expression of BRAF mRNA | 17562736 |
| D000242 | Cyclic AMP | Cyclic AMP results in increased activity of BRAF protein | 21693435 |
| D000242 | Cyclic AMP | Cyclic AMP results in increased activity of BRAF protein | 21693435 |
| D000242 | Cyclic AMP | [Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein | 21693435 |
| D000242 | Cyclic AMP | [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein | 21693435 |
| C016601 | afimoxifene | [BRAF protein co-treated with afimoxifene] results in increased expression of and results in increased activity of EGR1 protein | 25645941 |
| C016601 | afimoxifene | [BRAF protein co-treated with afimoxifene] results in increased phosphorylation of MAPK1 protein | 25645941 |
| C016601 | afimoxifene | [BRAF protein co-treated with afimoxifene] results in increased phosphorylation of MAPK3 protein | 25645941 |
| D000535 | Aluminum | [APP protein modified form binds to Aluminum] which results in decreased expression of BRAF mRNA | 21298039 |
| D000643 | Ammonium Chloride | Ammonium Chloride affects the expression of BRAF mRNA | 16483693 |
| D000880 | Anthraquinones | Anthraquinones analog results in decreased activity of BRAF protein mutant form | 27473261 |
| D018501 | Antirheumatic Agents | Antirheumatic Agents results in increased expression of BRAF mRNA | 24449571 |
| D001151 | Arsenic | Arsenic results in decreased expression of BRAF mRNA | 19654921 |
| C006632 | arsenic trioxide | arsenic trioxide results in decreased expression of BRAF mRNA | 24831965 |
| D001280 | Atrazine | Atrazine results in decreased expression of BRAF mRNA | 25929836 |
| C060988 | baohuoside I | baohuoside I inhibits the reaction [EGF protein results in increased phosphorylation of BRAF protein] | 25119583 |
| C060988 | baohuoside I | baohuoside I results in decreased phosphorylation of BRAF protein | 25119583 |
| C522781 | biflorin | biflorin affects the expression of BRAF mRNA | 27079618 |
| D020122 | tert-Butylhydroperoxide | tert-Butylhydroperoxide results in decreased expression of BRAF mRNA | 12419474 |
| D002104 | Cadmium | Cadmium results in decreased expression of BRAF mRNA | 21120746|2336940 |
| D002220 | Carbamazepine | Carbamazepine affects the expression of BRAF mRNA | 24752500 |
| D016572 | Cyclosporine | Cyclosporine results in increased expression of BRAF mRNA | 25562108 |
| C017160 | cypermethrin | cypermethrin results in increased expression of BRAF mRNA | 22528246 |
| C561627 | dabrafenib | BRAF protein mutant form results in increased susceptibility to dabrafenib | 26978007 |
| C561627 | dabrafenib | CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib] | 26978007 |
| C561627 | dabrafenib | dabrafenib results in decreased activity of BRAF protein | 20823850 |
| C561627 | dabrafenib | dabrafenib results in decreased activity of BRAF protein mutant form | 23237741 |
| C561627 | dabrafenib | MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib] | 26978007 |
| C561627 | dabrafenib | MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to dabrafenib] | 26978007 |
| C515055 | darinaparsin | darinaparsin results in decreased phosphorylation of BRAF protein | 25316819 |
| D002945 | Cisplatin | [Cisplatin co-treated with jinfukang] results in decreased expression of BRAF mRNA | 27392435 |
| D002945 | Cisplatin | [Cisplatin co-treated with Quercetin] results in increased expression of BRAF mRNA | 27514524 |
| D002945 | Cisplatin | Cisplatin results in increased expression of BRAF mRNA | 21151649 |
| D004008 | Diclofenac | Diclofenac affects the expression of BRAF mRNA | 24752500 |
| C036042 | dicyclohexyl phthalate | dicyclohexyl phthalate affects the expression of BRAF mRNA | 26924002 |
| D004041 | Dietary Fats | Dietary Fats results in increased expression of BRAF mRNA | 19030233 |
| D004041 | Dietary Fats | rimonabant inhibits the reaction [Dietary Fats results in increased expression of BRAF mRNA] | 19030233 |
| D004052 | Diethylnitrosamine | Diethylnitrosamine results in increased mutagenesis of BRAF gene | 15592514|2531945 |
| D015127 | 9,10-Dimethyl-1,2-benzanthracene | "9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BRAF mRNA" | 22485181 |
| C024629 | dimethyl phthalate | dimethyl phthalate affects the expression of BRAF mRNA | 26924002 |
| D004147 | Dioxins | Dioxins affects the expression of BRAF mRNA | 20463971 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol affects the expression of BRAF mRNA | 17555576 |
| D004997 | Ethinyl Estradiol | Ethinyl Estradiol results in increased expression of BRAF mRNA | 29097150 |
| D015738 | Famotidine | Famotidine results in decreased activity of BRAF protein | 20823850 |
| D005557 | Formaldehyde | Formaldehyde results in increased expression of BRAF mRNA | 23649840 |
| C574276 | GDC-0973 | "2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine promotes the reaction [BRAF protein mutant form results in increased susceptibility to GDC-0973]" | 22084396 |
| C574276 | GDC-0973 | BRAF protein mutant form results in increased susceptibility to GDC-0973 | 22084396 |
| C056507 | gemcitabine | gemcitabine results in decreased expression of BRAF mRNA | 20103597 |
| C544151 | jinfukang | [Cisplatin co-treated with jinfukang] results in decreased expression of BRAF mRNA | 27392435 |
| C544151 | jinfukang | jinfukang results in decreased expression of BRAF mRNA | 27392435 |
| C561695 | (+)-JQ1 compound | (+)-JQ1 compound results in increased expression of BRAF mRNA | 25961927 |
| D007649 | Ketamine | Ketamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of BRAF protein] | 19540866 |
| C045463 | leflunomide | leflunomide results in increased expression of BRAF mRNA | 28988120 |
| D008070 | Lipopolysaccharides | Ketamine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of BRAF protein] | 19540866 |
| D008070 | Lipopolysaccharides | Lipopolysaccharides results in increased phosphorylation of BRAF protein | 19540866 |
| C015329 | lycopene | lycopene results in decreased expression of BRAF protein | 17337101 |
| D058185 | Magnetite Nanoparticles | [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of BRAF mRNA | 26378955 |
| D008628 | Mercury | Mercury results in increased expression of BRAF mRNA | 19937285 |
| D008694 | Methamphetamine | Methamphetamine results in increased expression of BRAF mRNA | 19564919 |
| D008741 | Methyl Methanesulfonate | Methyl Methanesulfonate results in decreased expression of BRAF mRNA | 26011545 |
| D008741 | Methyl Methanesulfonate | Methyl Methanesulfonate results in increased expression of BRAF mRNA | 23649840 |
| C517284 | monomethyl phthalate | monomethyl phthalate affects the expression of BRAF mRNA | 26924002 |
| D037742 | Nanotubes, Carbon | "Nanotubes, Carbon analog results in decreased expression of BRAF mRNA" | 25554681 |
| D037742 | Nanotubes, Carbon | "Nanotubes, Carbon results in increased expression of BRAF mRNA" | 25620056 |
| D009532 | Nickel | Nickel results in decreased expression of BRAF mRNA | 25583101 |
| D009538 | Nicotine | Nicotine results in decreased expression of BRAF mRNA | 17135361 |
| D009538 | Nicotine | Nicotine results in decreased expression of BRAF protein | 17135361 |
| D052638 | Particulate Matter | Particulate Matter results in decreased expression of BRAF mRNA | 17987463 |
| C568608 | PCI 5002 | [PCI 5002 co-treated with Zinc] results in increased expression of BRAF mRNA | 18593933 |
| D010431 | Pentoxifylline | [Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein | 21693435 |
| D010634 | Phenobarbital | Phenobarbital affects the expression of BRAF mRNA | 19159669 |
| D010634 | Phenobarbital | Phenobarbital results in decreased expression of BRAF mRNA | 23091169 |
| C006253 | pirinixic acid | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of BRAF mRNA | 19710929 |
| C545373 | ponatinib | ponatinib analog results in decreased activity of BRAF protein | 21561767 |
| C545373 | ponatinib | ponatinib analog results in decreased activity of BRAF protein mutant form | 21561767 |
| C045950 | propiconazole | propiconazole results in decreased expression of BRAF mRNA | 21278054 |
| D011794 | Quercetin | [Cisplatin co-treated with Quercetin] results in increased expression of BRAF mRNA | 27514524 |
| C059514 | resveratrol | resveratrol results in decreased expression of BRAF protein modified form | 25280562 |
| C059514 | resveratrol | resveratrol results in decreased expression of BRAF protein modified form | 25280562 |
| D015474 | Isotretinoin | Isotretinoin results in decreased expression of BRAF mRNA | 20436886 |
| C089032 | rimonabant | rimonabant inhibits the reaction [Dietary Fats results in increased expression of BRAF mRNA] | 19030233 |
| D012834 | Silver | Silver affects the expression of BRAF mRNA | 27131904 |
| C009277 | sodium arsenate | sodium arsenate results in decreased expression of BRAF mRNA | 21795629 |
| C009277 | sodium arsenate | sodium arsenate results in increased expression of BRAF mRNA | 21795629 |
| C017947 | sodium arsenite | sodium arsenite affects the expression of BRAF protein | 17384772 |
| D012974 | Sodium Iodide | BRAF protein mutant form affects the reaction [TSHB protein affects the reaction [vemurafenib affects the uptake of Sodium Iodide]] | 26751190 |
| D012974 | Sodium Iodide | BRAF protein mutant form affects the reaction [TSHB protein affects the reaction [[vorinostat co-treated with vemurafenib] affects the uptake of Sodium Iodide]] | 26751190 |
| D018038 | Sodium Selenite | Sodium Selenite results in increased expression of BRAF mRNA | 16705456 |
| C471405 | sorafenib | sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein] | 17664273 |
| C471405 | sorafenib | sorafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein] | 17664273 |
| C471405 | sorafenib | sorafenib results in decreased activity of BRAF protein | 17341847|2082385 |
| C471405 | sorafenib | sorafenib results in decreased activity of BRAF protein mutant form | 17664273 |
| C471405 | sorafenib | sorafenib results in decreased activity of BRAF protein | 17341847 |
| C471405 | sorafenib | sorafenib binds to and results in decreased activity of BRAF protein | 16940797 |
| C471405 | sorafenib | sorafenib results in decreased activity of BRAF protein | 21128601 |
| D004113 | Succimer | [Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of BRAF mRNA | 26378955 |
| D013629 | Tamoxifen | Tamoxifen affects the expression of BRAF mRNA | 17555576 |
| D013806 | Theophylline | [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein | 21693435 |
| C560077 | trametinib | BRAF gene mutant form results in increased susceptibility to trametinib | 23432625 |
| C560077 | trametinib | BRAF mutant form results in increased susceptibility to trametinib | 22733540 |
| D014212 | Tretinoin | Tretinoin results in decreased expression of BRAF mRNA | 17045167 |
| C012589 | trichostatin A | trichostatin A results in decreased expression of BRAF mRNA | 24935251 |
| C000608764 | triphenyl(phenylethynyl)phosphonium | triphenyl(phenylethynyl)phosphonium results in decreased expression of BRAF protein | 26984758 |
| C016805 | tris(1,3-dichloro-2-propyl)phosphate | "tris(1,3-dichloro-2-propyl)phosphate results in increased expression of BRAF mRNA" | 26179874 |
| C057693 | troglitazone | troglitazone results in decreased expression of BRAF mRNA | 28973697 |
| C113580 | U 0126 | U 0126 inhibits the reaction [BRAF protein results in increased expression of PMAIP1 protein] | 20802529 |
| D017974 | Uranium Compounds | Uranium Compounds results in increased expression of BRAF mRNA | 19654044 |
| D014635 | Valproic Acid | Valproic Acid results in decreased expression of BRAF mRNA | 23179753|2493525 |
| D014638 | Vanadates | Vanadates results in increased expression of BRAF protein | 17874149 |
| D014639 | Vanadium | Vanadium results in decreased expression of BRAF mRNA | 19000753 |
| D001335 | Vehicle Emissions | Vehicle Emissions results in decreased expression of BRAF mRNA | 17987463 |
| D001335 | Vehicle Emissions | Vehicle Emissions results in increased expression of BRAF mRNA | 23535403 |
| D001335 | Vehicle Emissions | Vehicle Emissions results in increased methylation of BRAF gene | 25560391 |
| C551177 | vemurafenib | BRAF protein mutant form affects the reaction [TSHB protein affects the reaction [vemurafenib affects the uptake of Sodium Iodide]] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form affects the reaction [TSHB protein affects the reaction [[vorinostat co-treated with vemurafenib] affects the uptake of Sodium Iodide]] | 26751190 |
| C551177 | vemurafenib | A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]] | 27689874 |
| C551177 | vemurafenib | ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]] | 27689874 |
| C551177 | vemurafenib | BRAF gene mutant form results in increased susceptibility to vemurafenib | 21185263 |
| C551177 | vemurafenib | BRAF protein affects the reaction [vemurafenib results in decreased expression of CD70 protein] | 26828592 |
| C551177 | vemurafenib | BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TG mRNA] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TPO mRNA] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TG mRNA]] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TPO mRNA]] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form affects the susceptibility to vemurafenib | 26751190|2722224 |
| C551177 | vemurafenib | [BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA | 26751190 |
| C551177 | vemurafenib | [BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TG mRNA | 26751190 |
| C551177 | vemurafenib | [BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TPO mRNA | 26751190 |
| C551177 | vemurafenib | [BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA | 26751190 |
| C551177 | vemurafenib | [BRAF protein mutant form affects the susceptibility to vemurafenib] which results in decreased expression of TNFRSF10B protein | 27222248 |
| C551177 | vemurafenib | [BRAF protein mutant form affects the susceptibility to vemurafenib] which results in decreased phosphorylation of MAPK1 protein | 27222248 |
| C551177 | vemurafenib | [BRAF protein mutant form affects the susceptibility to vemurafenib] which results in decreased phosphorylation of MAPK3 protein | 27222248 |
| C551177 | vemurafenib | BRAF protein mutant form inhibits the reaction [vemurafenib results in increased phosphorylation of MAPK1 protein] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form inhibits the reaction [vemurafenib results in increased phosphorylation of MAPK3 protein] | 26751190 |
| C551177 | vemurafenib | BRAF protein mutant form results in increased susceptibility to vemurafenib | 26828592|2697800 |
| C551177 | vemurafenib | [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in decreased expression of CD70 protein | 26828592 |
| C551177 | vemurafenib | [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in decreased phosphorylation of MAPK1 protein | 27689874 |
| C551177 | vemurafenib | [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in decreased phosphorylation of MAPK3 protein | 27689874 |
| C551177 | vemurafenib | [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein | 27689874 |
| C551177 | vemurafenib | [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein | 27689874 |
| C551177 | vemurafenib | CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib] | 26978007 |
| C551177 | vemurafenib | MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib] | 26978007 |
| C551177 | vemurafenib | MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib] | 26978007 |
| C551177 | vemurafenib | [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib] | 27689874 |
| C551177 | vemurafenib | [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein] | 27689874 |
| C551177 | vemurafenib | [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein] | 27689874 |
| C551177 | vemurafenib | vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of BRAF protein] | 26640592 |
| C551177 | vemurafenib | vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein] | 26640592 |
| C551177 | vemurafenib | vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein] | 26640592 |
| C551177 | vemurafenib | vemurafenib results in decreased activity of BRAF protein | 20823850 |
| C551177 | vemurafenib | vemurafenib results in decreased activity of BRAF protein mutant form | 23237741|2485934 |
| C551177 | vemurafenib | vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]] | 26751190 |
| C551177 | vemurafenib | vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA] | 26751190 |
| C551177 | vemurafenib | vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TG mRNA] | 26751190 |
| C551177 | vemurafenib | vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TPO mRNA] | 26751190 |
| C551177 | vemurafenib | vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA] | 26751190 |
| C551177 | vemurafenib | BRAF mutant form affects the susceptibility to vemurafenib | 25477506 |
| C551177 | vemurafenib | vemurafenib results in decreased activity of BRAF protein | 21639808|2177047 |
| C551177 | vemurafenib | vemurafenib results in decreased activity of BRAF protein mutant form | 20973932|2118526 |
| C111237 | vorinostat | BRAF protein mutant form affects the reaction [TSHB protein affects the reaction [[vorinostat co-treated with vemurafenib] affects the uptake of Sodium Iodide]] | 26751190 |
| C111237 | vorinostat | BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]] | 26751190 |
| C111237 | vorinostat | BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TG mRNA]] | 26751190 |
| C111237 | vorinostat | BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TPO mRNA]] | 26751190 |
| C111237 | vorinostat | BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]] | 26751190 |
| C111237 | vorinostat | vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]] | 26751190 |
| C111237 | vorinostat | vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA] | 26751190 |
| C111237 | vorinostat | vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TG mRNA] | 26751190 |
| C111237 | vorinostat | vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TPO mRNA] | 26751190 |
| C111237 | vorinostat | vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA] | 26751190 |
| C111237 | vorinostat | vorinostat results in increased expression of BRAF mRNA | 27188386 |
| D014873 | Water Pollutants | Water Pollutants results in decreased expression of BRAF mRNA | 23591932 |
| D015032 | Zinc | [PCI 5002 co-treated with Zinc] results in increased expression of BRAF mRNA | 18593933 |
| GO ID | GO Term | Qualifier | Evidence | PubMed |
|---|---|---|---|---|
| GO:0004672 | protein kinase activity | - | IDA | 17563371 |
| GO:0004674 | protein serine/threonine kinase activity | - | IBA | 21873635 |
| GO:0004674 | protein serine/threonine kinase activity | - | IDA | 19667065 |
| GO:0005509 | calcium ion binding | - | IDA | 18567582 |
| GO:0005515 | protein binding | - | IPI | 12620389 15161933 15324660 16810323 16888650 17353931 17380122 17563371 17979178 18567582 20130576 20141835 21441910 21478863 22169110 22510884 22939624 23153539 23680146 23934108 24255178 24441586 24746704 25155755 25241761 25437913 25600339 26165597 26466569 26496610 27353360 |
| GO:0005524 | ATP binding | - | IEA | - |
| GO:0031267 | small GTPase binding | NOT | IPI | 12194967 |
| GO:0042802 | identical protein binding | - | IPI | 16858395 19727074 22169110 22510884 25155755 25437913 |
| GO ID | GO Term | Qualifier | Evidence | PubMed |
|---|---|---|---|---|
| GO:0000165 | MAPK cascade | - | IBA | 21873635 |
| GO:0000165 | MAPK cascade | - | TAS | - |
| GO:0000186 | activation of MAPKK activity | - | IEA | - |
| GO:0006468 | protein phosphorylation | - | IDA | 17563371 |
| GO:0009887 | animal organ morphogenesis | - | TAS | 9207797 |
| GO:0010628 | positive regulation of gene expression | - | IMP | 22065586 |
| GO:0010828 | positive regulation of glucose transmembrane transport | - | IDA | 23010278 |
| GO:0033138 | positive regulation of peptidyl-serine phosphorylation | - | IDA | 19667065 |
| GO:0043066 | negative regulation of apoptotic process | - | IDA | 19667065 |
| GO:0070374 | positive regulation of ERK1 and ERK2 cascade | - | IDA | 22065586 |
| GO:0070413 | trehalose metabolism in response to stress | - | IMP | 9837904 |
| GO:0071277 | cellular response to calcium ion | - | IDA | 18567582 |
| GO:0090150 | establishment of protein localization to membrane | - | IDA | 23010278 |
| GO ID | GO Term | Qualifier | Evidence | PubMed |
|---|---|---|---|---|
| GO:0005634 | nucleus | - | IEA | - |
| GO:0005739 | mitochondrion | - | IBA | 21873635 |
| GO:0005829 | cytosol | - | IBA | 21873635 |
| GO:0005829 | cytosol | - | IDA | - |
| GO:0005829 | cytosol | - | TAS | - |
| GO:0005886 | plasma membrane | - | IBA | 21873635 |
| GO:0005886 | plasma membrane | - | TAS | - |
| GO:0043231 | intracellular membrane-bounded organelle | - | IDA | - |
| KEGG ID | KEGG Term |
|---|---|
| hsa04010 | MAPK signaling pathway |
| hsa04012 | ErbB signaling pathway |
| hsa04062 | Chemokine signaling pathway |
| hsa04150 | mTOR signaling pathway |
| hsa04270 | Vascular smooth muscle contraction |
| hsa04510 | Focal adhesion |
| hsa04650 | Natural killer cell mediated cytotoxicity |
| hsa04720 | Long-term potentiation |
| hsa04722 | Neurotrophin signaling pathway |
| hsa04730 | Long-term depression |
| hsa04810 | Regulation of actin cytoskeleton |
| hsa04910 | Insulin signaling pathway |
| hsa04914 | Progesterone-mediated oocyte maturation |
| hsa05160 | Hepatitis C |
| hsa05200 | Pathways in cancer |
| hsa05210 | Colorectal cancer |
| hsa05211 | Renal cell carcinoma |
| hsa05212 | Pancreatic cancer |
| hsa05213 | Endometrial cancer |
| hsa05214 | Glioma |
| hsa05215 | Prostate cancer |
| hsa05216 | Thyroid cancer |
| hsa05218 | Melanoma |
| hsa05219 | Bladder cancer |
| hsa05220 | Chronic myeloid leukemia |
| hsa05221 | Acute myeloid leukemia |
| hsa05223 | Non-small cell lung cancer |
| Reactome ID | Reactome Term | Evidence |
|---|---|---|
| R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission | TAS |
| R-HSA-112315 | Transmission across Chemical Synapses | TAS |
| R-HSA-112316 | Neuronal System | TAS |
| R-HSA-1295596 | Spry regulation of FGF signaling | TAS |
| R-HSA-162582 | Signal Transduction | TAS |
| R-HSA-162582 | Signal Transduction | IEA |
| R-HSA-1643685 | Disease | TAS |
| R-HSA-166520 | Signaling by NTRKs | IEA |
| R-HSA-169893 | Prolonged ERK activation events | IEA |
| R-HSA-170968 | Frs2-mediated activation | IEA |
| R-HSA-170984 | ARMS-mediated activation | IEA |
| R-HSA-187037 | Signaling by NTRK1 (TRKA) | IEA |
| R-HSA-187687 | Signalling to ERKs | IEA |
| R-HSA-187706 | Signalling to p38 via RIT and RIN | IEA |
| R-HSA-190236 | Signaling by FGFR | TAS |
| R-HSA-438064 | Post NMDA receptor activation events | TAS |
| R-HSA-442742 | CREB phosphorylation through the activation of Ras | TAS |
| R-HSA-442755 | Activation of NMDA receptor and postsynaptic events | TAS |
| R-HSA-5654726 | Negative regulation of FGFR1 signaling | TAS |
| R-HSA-5654727 | Negative regulation of FGFR2 signaling | TAS |
| R-HSA-5654732 | Negative regulation of FGFR3 signaling | TAS |
| R-HSA-5654733 | Negative regulation of FGFR4 signaling | TAS |
| R-HSA-5654736 | Signaling by FGFR1 | TAS |
| R-HSA-5654738 | Signaling by FGFR2 | TAS |
| R-HSA-5654741 | Signaling by FGFR3 | TAS |
| R-HSA-5654743 | Signaling by FGFR4 | TAS |
| R-HSA-5663202 | Diseases of signal transduction | TAS |
| R-HSA-5673000 | RAF activation | TAS |
| R-HSA-5673001 | RAF/MAP kinase cascade | TAS |
| R-HSA-5674135 | MAP2K and MAPK activation | TAS |
| R-HSA-5674499 | Negative feedback regulation of MAPK pathway | TAS |
| R-HSA-5675221 | Negative regulation of MAPK pathway | TAS |
| R-HSA-5683057 | MAPK family signaling cascades | TAS |
| R-HSA-5684996 | MAPK1/MAPK3 signaling | TAS |
| R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants | TAS |
| R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants | TAS |
| R-HSA-6802949 | Signaling by RAS mutants | TAS |
| R-HSA-6802952 | Signaling by BRAF and RAF fusions | TAS |
| R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF | TAS |
| R-HSA-6802957 | Oncogenic MAPK signaling | TAS |
| R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | TAS |
| R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | IEA |
| PMID | Title (Year) | Author | Journal |
|---|---|---|---|
| 25350766 | Epidemiology of goblet cell and microvesicular hyperplastic polyps. (2014 Dec) | Qazi TM | Am J Gastroenterol |
| 28065467 | Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases. (2017 Jul) | Rokutan-Kurata M | Clin Lung Cancer |
| 17148775 | Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. (2006 Dec 6) | Samowitz WS | J Natl Cancer Inst |
| 21325950 | Risk factors for sessile serrated adenomas. (2011 Sep) | Anderson JC | J Clin Gastroenterol |
| 29511884 | Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma. (2018 May) | Nakasone S | J Cancer Res Clin Oncol |
| 25126481 | Establishment and characterization of a singaporean chinese lung adenocarcinoma cell line with four copies of the epidermal growth factor receptor gene. (2014 Aug 1) | Choong ML | Biores Open Access |
| 26527886 | SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas. (2015) | Zheng S | Onco Targets Ther |
| 23515407 | Characteristics of lung cancers harboring NRAS mutations. (2013 May 1) | Ohashi K | Clin Cancer Res |
| 25789627 | Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. (2015) | Hsu KH | PLoS One |
| 26200269 | Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. (2015 Aug) | Shim HS | J Thorac Oncol |
| 22317764 | Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. (2012 Apr 1) | Zhang Y | Clin Cancer Res |
| 29167001 | [Association between the ALK Gene Status and the Efficacy of First-line Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma]. (2017 Nov 20) | Chen M | Zhongguo Fei Ai Za Zhi |
| 26927717 | Pulmonary Langerhans Cell Histiocytosis: An Update From the Pathologists' Perspective. (2016 Mar) | Roden AC | Arch Pathol Lab Med |
| 28325255 | Mucosal melanoma of the head and neck. (2017 Apr) | Ascierto PA | Crit Rev Oncol Hematol |
| 28921583 | Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. (2018 Jan 15) | Jayasekara H | Int J Cancer |
| 23539450 | Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. (2013 May 1) | Burnett-Hartman AN | Cancer Res |
| 26893860 | Genetic alterations in lung adenocarcinoma with a micropapillary component. (2016 Feb) | Furukawa M | Mol Clin Oncol |
| 22975805 | The transcriptional landscape and mutational profile of lung adenocarcinoma. (2012 Nov) | Seo JS | Genome Res |
| 26423386 | Postdiagnostic intake of one-carbon nutrients and alcohol in relation to colorectal cancer survival. (2015 Nov) | Lochhead P | Am J Clin Nutr |
| 24625419 | BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. (2014 Apr) | Roden AC | Am J Surg Pathol |
| 23098378 | Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. (2013 Jan) | Li H | Lung Cancer |
| 29631966 | MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. (2018 Mar 17) | Reis H | Clin Lung Cancer |
| 27298405 | Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer. (2016 Aug 20) | Rusthoven CG | J Clin Oncol |
| 23802852 | Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. (2014 Mar) | McQuitty E | Arch Pathol Lab Med |
| 26202550 | Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. (2015 Dec) | Zheng D | Ann Surg Oncol |
| 23877438 | CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. (2013 Oct) | Matsuura S | Oncol Rep |
| 24850843 | FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. (2014 Aug 1) | Wang R | Clin Cancer Res |
| 27001591 | Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient. (2016 May 1) | Presley CJ | J Clin Oncol |
| 23744164 | The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy. (2013) | Nicos M | Pneumonol Alergol Pol |
| 29301504 | Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report. (2018 Jan 4) | Arakawa K | BMC Cancer |
| 25567908 | Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. (2015 Aug 15) | Drilon A | Clin Cancer Res |
| 23988776 | EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. (2014 Mar) | Warth A | Eur Respir J |
| 25366782 | Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer. (2014 Oct 31) | Han Y | Genet Mol Res |
| 22707299 | Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. (2012 Nov) | Ren S | Cell Biochem Biophys |
| 25351745 | MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. (2015 Apr 15) | Arcila ME | Clin Cancer Res |
| 28881815 | Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. (2017 Aug 8) | Dugay F | Oncotarget |
| 22430133 | Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. (2011-2012) | Xu J | Cancer Biomark |
| 22407457 | Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. (2012 Jun) | Choi H | Int J Oncol |
| 26955281 | The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. (2016) | Zheng D | Onco Targets Ther |
| 17035382 | The case for a genetic predisposition to serrated neoplasia in the colorectum: hypothesis and review of the literature. (2006 Oct) | Young J | Cancer Epidemiol Biomarkers Prev |
| 20507599 | Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. (2010 May 27) | Baba Y | Mol Cancer |
| 25234657 | Tongue carcinoma infrequently harbor common actionable genetic alterations. (2014 Sep 19) | Tan DS | BMC Cancer |
| 26164066 | Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. (2015 Sep) | Preusser M | Eur J Cancer |
| 23788674 | A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. (2013 Jul 1) | Nishihara R | Am J Epidemiol |
| 25152623 | Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. (2014) | Hu H | Onco Targets Ther |
| 28689173 | Current understanding and management of pulmonary Langerhans cell histiocytosis. (2017 Oct) | Vassallo R | Thorax |
| 25288236 | Molecular alterations in non-small cell lung carcinomas of the young. (2014 Dec) | VandenBussche CJ | Hum Pathol |
| 25870798 | Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. (2015 Apr) | Kohno T | Transl Lung Cancer Res |
| 24729716 | Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. (2014) | Li H | Onco Targets Ther |
| 29083024 | Pulmonary Langerhans' cell histiocytosis in adults. (2017) | Radzikowska E | Adv Respir Med |
| 25280443 | Association between molecular subtypes of colorectal cancer and patient survival. (2015 Jan) | Phipps AI | Gastroenterology |
| 27008586 | Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer. (2017 Jan) | Bu S | Ann Surg Oncol |
| 28468033 | [Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. (2017 May 8) | Hou LK | Zhonghua Bing Li Xue Za Zhi |
| 23547084 | Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147. (2013 Jun 1) | Phipps AI | J Clin Oncol |
| 28776576 | GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas. (2017 Dec) | Ritterhouse LL | Mod Pathol |
| 26200454 | Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. (2015 Oct) | Gautschi O | J Thorac Oncol |
| 24448365 | Influence of pre-diagnostic cigarette smoking on colorectal cancer survival: overall and by tumour molecular phenotype. (2014 Mar 4) | Zhu Y | Br J Cancer |
| 27262212 | Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis. (2016 Aug) | Noonan SA | J Thorac Oncol |
| 29467863 | Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma. (2018 Mar) | Yang Y | Oncol Lett |
| 25789184 | Pulmonary Langerhans Cell Histiocytosis with Lytic Bone Involvement in an Adult Smoker: Regression following Smoking Cessation. (2015) | Routy B | Case Rep Hematol |
| 25862146 | PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. (2015 Jun) | Chang YL | Lung Cancer |
| 22768234 | Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. (2012) | An SJ | PLoS One |
| 25587051 | Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. (2015 Mar) | Weisenberger DJ | Cancer Epidemiol Biomarkers Prev |
| 25310214 | Langerhans cell histiocytosis. (2014 Oct) | Grana N | Cancer Control |
| 28383426 | A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer. (2017 Apr) | Cui G | Medicine (Baltimore) |
| 29413057 | Tumor biomarker testing in non-small-cell lung cancer: A decade of change. (2018 Feb) | VanderLaan PA | Lung Cancer |
| 24979348 | BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis. (2014) | Chen D | PLoS One |
| 26003197 | [Pulmonary manifestations of Langerhans cell histiocytosis]. (2015 Oct) | Obert J | Rev Mal Respir |
| 21483012 | Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. (2011 May 20) | Paik PK | J Clin Oncol |
| 26530529 | Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. (2015 Nov 24) | Li W | Oncotarget |
| 26102513 | Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma. (2015) | Shan L | PLoS One |
| 29246019 | Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. (2017 Nov 21) | Liu R | Oncotarget |
| 28220299 | Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. (2017 Apr) | Dimmler A | Virchows Arch |
| 29413048 | Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? (2018 Feb) | Zhou F | Lung Cancer |
| 27033383 | [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. (2016 Apr 8) | Chen LF | Zhonghua Bing Li Xue Za Zhi |
| 27438512 | Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer. (2018 Apr) | Jia X | Appl Immunohistochem Mol Morphol |
| 26711930 | Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. (2016 Jan) | Tissot C | Lung Cancer |
| 27565922 | Hot spot mutations in Finnish non-small cell lung cancers. (2016 Sep) | Maki-Nevala S | Lung Cancer |
| 25007143 | Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. (2014 Dec) | Boland JM | Am J Surg Pathol |
| 23150706 | RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. (2012 Dec 10) | Wang R | J Clin Oncol |
| 26116215 | A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers. (2015 Aug 1) | Wang M | Am J Epidemiol |
| 26915300 | Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease. (2016 Sep) | Kamionek M | Histopathology |
| 27258560 | The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma. (2018 Feb) | Skalova A | Appl Immunohistochem Mol Morphol |
| 25013126 | Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic study. (2014 Sep 15) | Xicola RM | Clin Cancer Res |
| 24743704 | Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. (2014 May 27) | Li S | Br J Cancer |
| 26208325 | Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. (2015) | Chatziandreou I | PLoS One |
| 27027665 | Gene aberrations for precision medicine against lung adenocarcinoma. (2016 Jun) | Saito M | Cancer Sci |
| 25745045 | No impact of passive smoke on the somatic profile of lung cancers in never-smokers. (2015 May) | Couraud S | Eur Respir J |
| 28280984 | Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. (2018 Jan) | Saito M | Surg Today |
| 17096326 | Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. (2007 Feb 1) | Slattery ML | Int J Cancer |
| 27816338 | [Adult Langerhans cell histiocytosis]. (2017 Jan) | de Menthon M | Presse Med |
| 26775573 | [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]. (2016 Jan) | Hamard C | Ann Pathol |
| 19959686 | Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer. (2009 Dec) | Curtin K | Cancer Epidemiol Biomarkers Prev |
| 19369630 | Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. (2009 May) | De Oliveira Duarte Achcar R | Am J Clin Pathol |
| 29312770 | Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung. (2017 Dec) | Kalchiem-Dekel O | J Thorac Dis |
| 18594528 | Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. (2008 Jul 22) | Koivunen JP | Br J Cancer |
| 25738220 | Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. (2015 May) | Sholl LM | J Thorac Oncol |
| 23238028 | Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy. (2012 Jan 5) | Buda A | Clin Transl Gastroenterol |
| 22507644 | Human papillomavirus and gene mutations in head and neck squamous carcinomas. (2012 May) | Friedland P | ANZ J Surg |
| 24055406 | Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. (2013 Nov) | Hosgood HD 3rd | Respir Med |
| 23723294 | Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). (2013 Sep) | Dearden S | Ann Oncol |
| 27231182 | A Case of Pulmonary Langerhans Cell Histiocytosis with BRAF V600E-negative and MAP2K1-posivtive Mutations Presenting as Diffuse Nodules in Chest High-resolution Computed Tomography After Smoking Cessation. (2016 Jun 5) | Li Y | Chin Med J (Engl) |
| 28840008 | Differences between low and high grade fetal adenocarcinoma of the lung: a clinicopathological and molecular study. (2017 Jul) | Zhang J | J Thorac Dis |
| 25657019 | BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. (2015 May) | Couraud S | Eur Respir J |
| 29650325 | Improving the genetic signature of prostate cancer, the somatic mutations. (2018 Jun) | Martinez-Gonzalez LJ | Urol Oncol |
| 29683890 | Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. (2018 Apr 20) | Tseng JS | J Immunother |
| 20125129 | Hyperplastic polyposis syndrome is associated with cigarette smoking, which may be a modifiable risk factor. (2010 Jul) | Walker RG | Am J Gastroenterol |
| 28877978 | How I manage pulmonary Langerhans cell histiocytosis. (2017 Sep 30) | Lorillon G | Eur Respir Rev |
| 20200438 | Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. (2010 Mar) | Rozek LS | Cancer Epidemiol Biomarkers Prev |
| 20587792 | Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. (2010 Jul 21) | Limsui D | J Natl Cancer Inst |
| 26851496 | Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population. (2016 May) | Leduc N | J Thorac Oncol |
| 26116372 | MiR-21: an environmental driver of malignant melanoma? (2015 Jun 27) | Melnik BC | J Transl Med |
| 29137260 | Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma. (2017 Oct 10) | Dong Y | Oncotarget |
| 26064214 | Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis. (2015) | Chen K | Int J Clin Exp Med |
| 23376323 | Clinical subtypes and molecular characteristics of serrated polyposis syndrome. (2013 Jun) | Guarinos C | Clin Gastroenterol Hepatol |
| 24163741 | Molecular biology of lung cancer. (2013 Oct) | Cooper WA | J Thorac Dis |
| 24137465 | Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system. (2013 Oct) | Krawczyk P | Oncol Lett |
| 26599269 | Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. (2015) | Gautschi O | Oncol Res Treat |
| 29217530 | The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2). (2018 Mar 1) | Aisner DL | Clin Cancer Res |
| 22969966 | Braf and erbB2 mutations correlate with smoking status in lung cancer patients. (2012 May) | Sasaki H | Exp Ther Med |